US5108909A
(en)
*
|
1985-03-22 |
1992-04-28 |
Chiron Corporation |
Expression of TPA in mammalian cells
|
DE3676604D1
(de)
*
|
1985-03-22 |
1991-02-07 |
Chiron Corp |
Expression von epa in saeugetierzellen.
|
US4935352A
(en)
*
|
1985-10-21 |
1990-06-19 |
Takeda Chemical Industries, Ltd. |
Expression vector for animal cell line and use thereof
|
CA1297435C
(en)
*
|
1986-09-12 |
1992-03-17 |
Stephen D. Gillies |
Messenger rna stabilization in animal cells
|
AU613876B2
(en)
*
|
1986-10-01 |
1991-08-15 |
Merck & Co., Inc. |
Synthetic genes encoding proteins from plasmid containing eucaryotic secretory signal peptides and process for secreting encoded proteins
|
PT86162B
(pt)
*
|
1986-11-21 |
1990-11-20 |
Smithkline Beecham Corp |
Expressao de proteina recombinante
|
ZA879286B
(en)
|
1986-12-16 |
1988-10-26 |
Smith Kline Rit |
New plasminogen activators
|
GB8717430D0
(en)
*
|
1987-07-23 |
1987-08-26 |
Celltech Ltd |
Recombinant dna product
|
EP0784681A1
(de)
*
|
1994-10-06 |
1997-07-23 |
Warner-Lambert Company |
Verfahren zur anwendung von scavenger-rezeptorproteine für behandlung von atherosclerose
|
US5641665A
(en)
|
1994-11-28 |
1997-06-24 |
Vical Incorporated |
Plasmids suitable for IL-2 expression
|
CA2257357C
(en)
*
|
1996-06-07 |
2010-04-13 |
Neorx Corporation |
Humanized antibodies with modified glycosylation
|
US5846946A
(en)
|
1996-06-14 |
1998-12-08 |
Pasteur Merieux Serums Et Vaccins |
Compositions and methods for administering Borrelia DNA
|
US6156567A
(en)
*
|
1996-07-03 |
2000-12-05 |
Merial |
Truncated transcriptionally active cytomegalovirus promoters
|
US20030109680A1
(en)
*
|
2001-11-21 |
2003-06-12 |
Sunol Molecular Corporation |
Antibodies for inhibiting blood coagulation and methods of use thereof
|
US5986065A
(en)
*
|
1997-03-10 |
1999-11-16 |
Sunol Molecular Corporation |
Antibodies for inhibiting blood coagulation and methods of use thereof
|
US7749498B2
(en)
*
|
1997-03-10 |
2010-07-06 |
Genentech, Inc. |
Antibodies for inhibiting blood coagulation and methods of use thereof
|
US20060235209A9
(en)
*
|
1997-03-10 |
2006-10-19 |
Jin-An Jiao |
Use of anti-tissue factor antibodies for treating thromboses
|
US6517843B1
(en)
|
1999-08-31 |
2003-02-11 |
Merial |
Reduction of porcine circovirus-2 viral load with inactivated PCV-2
|
KR100382720B1
(ko)
*
|
2000-08-30 |
2003-05-09 |
삼성전자주식회사 |
반도체 식각 장치 및 이를 이용한 반도체 소자의 식각 방법
|
FR2823222B1
(fr)
|
2001-04-06 |
2004-02-06 |
Merial Sas |
Vaccin contre le virus de la fievre du nil
|
PT1436397E
(pt)
|
2001-10-11 |
2010-07-15 |
Angeletti P Ist Richerche Bio |
Vacina de v�rus da hepatite c
|
EP1436397B1
(de)
|
2001-10-11 |
2010-05-12 |
Merck Sharp & Dohme Corp. |
Hepatitis-c-virus-impfstoff
|
US20030190705A1
(en)
*
|
2001-10-29 |
2003-10-09 |
Sunol Molecular Corporation |
Method of humanizing immune system molecules
|
WO2003049763A1
(en)
*
|
2001-12-12 |
2003-06-19 |
Fh Faulding & Co Limited |
Composition for the preservation of viruses
|
DE60226896D1
(de)
*
|
2001-12-17 |
2008-07-10 |
Crucell Holland Bv |
Herstellung von f(ab')2 fragmenten in saügetierzelle
|
JP2006516883A
(ja)
|
2002-09-19 |
2006-07-13 |
アメリカ合衆国 |
P.アリアシポリペプチド、ユウガイサシチョウバエポリペプチド、および使用法
|
ATE429487T1
(de)
|
2002-10-29 |
2009-05-15 |
Us Gov Health & Human Serv |
Lutzomyia longipalpis-polypeptide und verwendungsverfahren
|
DE10256083A1
(de)
|
2002-11-29 |
2004-08-12 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Expressionsvektor, Verfahren zur Herstellung von heterologen Genprodukten und Selektionsverfahren für hochproduzierende rekombinante Zellen
|
US7384744B2
(en)
*
|
2002-11-29 |
2008-06-10 |
Boehringer Ingelheim Pharma Gmbh & Co., Kg |
Expression vector, methods for the production of heterologous gene products and for the selection of recombinant cells producing high levels of such products
|
US7468273B2
(en)
|
2003-05-01 |
2008-12-23 |
Meial Limited |
Canine GHRH gene, polypeptides and methods of use
|
CA2530980A1
(en)
*
|
2003-06-19 |
2005-01-20 |
Tanox, Inc. |
Tissue factor-specific antibodies for preventing or treating acute lung injury or acute respiratory distress syndrome
|
DE10338531A1
(de)
|
2003-08-19 |
2005-04-07 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Verfahren zur Reklonierung von Produktionszellen
|
US20050064547A1
(en)
*
|
2003-09-24 |
2005-03-24 |
Brown Arthur M. |
Vectors and transfected cells
|
GB0324044D0
(en)
*
|
2003-10-14 |
2003-11-19 |
Astrazeneca Ab |
Protein
|
GB0330079D0
(en)
*
|
2003-12-20 |
2004-02-04 |
Bioinvent Int Ab |
Vaccine
|
CA2553676A1
(en)
*
|
2004-01-28 |
2005-08-11 |
Research Development Foundation |
Human soluble neuropilin-1 primary polyadenylation signal and uses thereof
|
US20060040354A1
(en)
*
|
2004-07-20 |
2006-02-23 |
O'keefe Theresa L |
Novel polyadenylation signal for use in expression vectors
|
BRPI0609120A2
(pt)
*
|
2005-04-13 |
2010-11-16 |
Astrazeneca Ab |
célula, vetor, e, métodos para produzir proteìna gama-carboxilada e para produzir uma composição farmacêutica
|
PT1881845E
(pt)
|
2005-04-25 |
2010-05-31 |
Merial Ltd |
Vacinas de vírus nipah
|
US9056090B2
(en)
*
|
2005-06-17 |
2015-06-16 |
Msd Italia Srl |
Hepatitis C virus nucleic acid vaccine
|
US20080241184A1
(en)
|
2005-08-25 |
2008-10-02 |
Jules Maarten Minke |
Canine influenza vaccines
|
JP2009515529A
(ja)
|
2005-11-14 |
2009-04-16 |
メリアル リミテッド |
腎不全のための遺伝子療法
|
US7771995B2
(en)
|
2005-11-14 |
2010-08-10 |
Merial Limited |
Plasmid encoding human BMP-7
|
EP1996705B1
(de)
*
|
2006-03-20 |
2011-08-31 |
ChromaGenics B.V. |
Die expression verstärkende dna-fragmente, deren verwendung und verfahren zum finden dieser
|
GB0606190D0
(en)
*
|
2006-03-28 |
2006-05-10 |
Isis Innovation |
Construct
|
EP2759307B1
(de)
|
2006-03-29 |
2016-11-09 |
Merial Limited |
Impfstoff gegen Streptokokken
|
US7862821B2
(en)
|
2006-06-01 |
2011-01-04 |
Merial Limited |
Recombinant vaccine against bluetongue virus
|
US20080124760A1
(en)
|
2006-07-26 |
2008-05-29 |
Barbara Enenkel |
Regulatory Nucleic Acid Elements
|
DE102006039003A1
(de)
|
2006-08-19 |
2008-02-21 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue Verbindungen
|
JP2010525812A
(ja)
|
2007-05-02 |
2010-07-29 |
メリアル リミテッド |
発現及び安定性が改善されたdnaプラスミド
|
US8206967B2
(en)
*
|
2007-07-06 |
2012-06-26 |
Medimmune Limited |
Method for production of recombinant human thrombin
|
EP2025675A1
(de)
|
2007-08-14 |
2009-02-18 |
Boehringer Ingelheim International GmbH |
Arylsulfonamide mit analgetischer Wirkung
|
EA201000296A1
(ru)
|
2007-08-14 |
2010-08-30 |
Бёрингер Ингельхайм Интернациональ Гмбх |
Новые соединения
|
FR2920158B1
(fr)
*
|
2007-08-24 |
2010-03-12 |
Centre Nat Rech Scient |
Production de plasmides et expression de proteines recombinantes dans des cellules cultivees sans antibiotiques
|
WO2009036280A1
(en)
*
|
2007-09-12 |
2009-03-19 |
Copernicus Therapeutics, Inc. |
Long-term in vivo transgene expression
|
EP2283035B1
(de)
|
2008-05-08 |
2015-07-29 |
Merial Limited |
Leishmania impfstoff unter verwendung von sandmücken speichelimmunogen
|
SG192541A1
(en)
|
2008-07-23 |
2013-08-30 |
Boehringer Ingelheim Pharma |
Novel regulatory elements
|
MY159543A
(en)
|
2008-11-28 |
2017-01-13 |
Merial Inc |
Recombinant avian influenza vaccine and uses thereof
|
CN103585643A
(zh)
|
2009-04-03 |
2014-02-19 |
梅里亚有限公司 |
运载新城疫病毒的禽疫苗
|
HUE031597T2
(en)
|
2009-05-22 |
2017-07-28 |
Merial Inc |
Antibiotic-free plasmid
|
PE20121685A1
(es)
|
2009-12-28 |
2012-12-28 |
Merial Ltd |
Antigeno ndv recombinante y usos del mismo
|
US20130197612A1
(en)
|
2010-02-26 |
2013-08-01 |
Jack W. Lasersohn |
Electromagnetic Radiation Therapy
|
CA2792117C
(en)
|
2010-03-12 |
2016-09-20 |
Merial Limited |
Foot and mouth disease virus recombinant vaccines and uses thereof
|
JP5913316B2
(ja)
|
2010-08-31 |
2016-04-27 |
メリアル リミテッド |
ニューカッスル病ウイルスをベクターとするヘルペスウイルスワクチン
|
US8771709B2
(en)
|
2010-09-20 |
2014-07-08 |
Crucell Holland B.V. |
Therapeutic vaccination against active Tuberculosis
|
MX354752B
(es)
|
2010-09-27 |
2018-03-20 |
Janssen Vaccines & Prevention Bv |
Regimen de vacunacion de sensibilizacion y refuerzo heterologo contra malaria.
|
US20120244209A1
(en)
|
2011-03-02 |
2012-09-27 |
Roth Jack A |
Tusc2 therapies
|
WO2012145577A1
(en)
|
2011-04-20 |
2012-10-26 |
Merial Limited |
Adjuvanted rabies vaccine with improved viscosity profile
|
MX361804B
(es)
|
2011-05-27 |
2018-12-17 |
Boehringer Ingelheim Animal Health Usa Inc |
Vacunas genéticas contra el virus hendra y el virus nipah.
|
US9669085B2
(en)
|
2011-06-01 |
2017-06-06 |
Merial Inc. |
Needle-free administration of PRRSV vaccines
|
BR112014001287B1
(pt)
|
2011-07-20 |
2020-12-08 |
Centre National De La Recherche Scientifique |
vacina recombinante do vírus da leucemia felina contendo gene otimizado do envelope do vírus da leucemia felina
|
MX362393B
(es)
*
|
2011-12-07 |
2019-01-15 |
Glenmark Pharmaceuticals Sa |
Cassette de expresion.
|
WO2013092743A2
(en)
|
2011-12-22 |
2013-06-27 |
F. Hoffmann-La Roche Ag |
Expression vector element combinations, novel production cell generation methods and their use for the recombinant production of polypeptides
|
CA2853955C
(en)
|
2011-12-22 |
2021-09-28 |
F. Hoffmann-La Roche Ag |
Expression vector organization, novel production cell generation methods and their use for the recombinant production of polypeptides
|
CA2864106C
(en)
|
2012-02-14 |
2017-10-17 |
Merial Limited |
Rotavirus subunit vaccines and methods of making and use thereof
|
EP2814506B1
(de)
|
2012-02-14 |
2018-11-28 |
Merial, Inc. |
Sowohl tollwut- als auch ox40-proteine exprimierende rekombinante poxvirusvektoren und daraus hergestellte impfstoffe
|
US8932607B2
(en)
|
2012-03-12 |
2015-01-13 |
Crucell Holland B.V. |
Batches of recombinant adenovirus with altered terminal ends
|
NZ628385A
(en)
|
2012-03-12 |
2016-09-30 |
Crucell Holland Bv |
Batches of recombinant adenovirus with altered terminal ends
|
ES2711878T3
(es)
|
2012-03-20 |
2019-05-08 |
Merial Inc |
Vacuna contra el virus del herpes equino 1 recombinante que contiene glicoproteína C mutada y usos de la misma
|
US9125870B2
(en)
|
2012-03-22 |
2015-09-08 |
Crucell Holland B.V. |
Vaccine against RSV
|
CN105431169B
(zh)
|
2012-03-22 |
2019-04-02 |
扬森疫苗与预防公司 |
抗rsv疫苗
|
ES2664069T3
(es)
|
2012-06-13 |
2018-04-18 |
Merial, Inc. |
Vacunas contra BTV y AHSV de genoma reordenado
|
WO2014102103A2
(en)
|
2012-12-31 |
2014-07-03 |
Boehringer Ingelheim International Gmbh |
Heterologous intron within a signal peptide
|
WO2014102101A1
(en)
|
2012-12-31 |
2014-07-03 |
Boehringer Ingelheim International Gmbh |
Novel intron sequences
|
CN110894226A
(zh)
|
2013-01-17 |
2020-03-20 |
汉诺威医学院 |
用于治疗或预防疾病的因子1蛋白、因子2蛋白及其抑制剂
|
JP6469081B2
(ja)
|
2013-04-25 |
2019-02-13 |
ヤンセン ファッシンズ アンド プリベンション ベーフェーJanssen Vaccines & Prevention B.V. |
安定化された可溶性融合前rsvfポリペプチド
|
WO2014182972A2
(en)
|
2013-05-10 |
2014-11-13 |
The Regents Of The University Of California |
Diagnostic and monitoring system for huntington's disease
|
EP3010931B1
(de)
|
2013-06-17 |
2018-06-13 |
Janssen Vaccines & Prevention B.V. |
Stabilisierte lösliche präfusionierte rsv-f-polypeptide
|
WO2015073707A1
(en)
|
2013-11-15 |
2015-05-21 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods of treating heart failure with agonists of hypocretin receptor 2
|
EP3215188A1
(de)
|
2014-11-03 |
2017-09-13 |
Merial, Inc. |
Verfahren zur verwendung von mikronadelimpfstoffformulierungen zur anregung von schützender immunität gegen das tollwutvirus bei tieren
|
WO2016071306A1
(en)
|
2014-11-04 |
2016-05-12 |
Crucell Holland B.V. |
Therapeutic hpv16 vaccines
|
AU2015358890B2
(en)
|
2014-12-10 |
2019-06-13 |
Opko Biologics Ltd. |
Methods of producing long acting CTP-modified growth hormone polypeptides
|
US10570417B2
(en)
|
2015-04-14 |
2020-02-25 |
Janssen Vaccines & Prevention B.V. |
Recombinant adenovirus expressing two transgenes with a bidirectional promoter
|
EP3889166A1
(de)
|
2015-06-23 |
2021-10-06 |
Boehringer Ingelheim Animal Health USA Inc. |
Rekombinante prrsv-virusvektoren mit minor-protein und verfahren zur herstellung und verwendung davon
|
WO2017005848A1
(en)
|
2015-07-07 |
2017-01-12 |
Janssen Vaccines & Prevention B.V. |
Stabilized soluble pre-fusion rsv f polypeptides
|
US10456462B2
(en)
|
2015-07-07 |
2019-10-29 |
Janssen Vaccines & Preventions B.V. |
Vaccine against RSV
|
BR112018003019A2
(pt)
|
2015-08-20 |
2018-09-25 |
Janssen Vaccines & Prevention Bv |
vacinas terapêuticas contra hpv18
|
CA2996143A1
(en)
|
2015-08-20 |
2017-02-23 |
Merial, Inc. |
Fcv recombinant vaccines and uses thereof
|
AU2016316723B2
(en)
|
2015-09-02 |
2021-03-25 |
Janssen Vaccines & Prevention B.V. |
Stabilized viral class I fusion proteins
|
CA3000352A1
(en)
|
2015-09-29 |
2017-04-06 |
Merial, Inc. |
Canine parvovirus (cpv) virus-like particle (vlp) vaccines and uses thereof
|
ES2899230T3
(es)
|
2015-11-23 |
2022-03-10 |
Boehringer Ingelheim Animal Health Usa Inc |
Proteínas de fusión de FMDV y E2 y usos de las mismas
|
EP3400290B1
(de)
|
2016-01-08 |
2023-04-05 |
Replimune Limited |
Onkolytischer virusstamm
|
TWI760322B
(zh)
|
2016-01-29 |
2022-04-11 |
美商百靈佳殷格翰動物保健美國有限公司 |
重組腺病毒載體裝載之fmdv疫苗及其用途
|
PL3439672T3
(pl)
|
2016-04-05 |
2021-06-14 |
Janssen Vaccines & Prevention B.V. |
Stabilizowane rozpuszczalne białko f rsv przed fuzją do zastosowania w profilaktyce zakażenia rsv
|
MX2018012095A
(es)
|
2016-04-05 |
2019-01-10 |
Janssen Vaccines & Prevention Bv |
Vacuna contra vrs.
|
CN109922829A
(zh)
|
2016-05-02 |
2019-06-21 |
扬森疫苗与预防公司 |
治疗性hpv疫苗组合
|
CA3023322A1
(en)
|
2016-05-12 |
2017-11-16 |
Janssen Vaccines & Prevention B.V. |
Potent and balanced bidirectional promoter
|
MX2018014699A
(es)
|
2016-05-30 |
2019-02-28 |
Janssen Vaccines & Prevention Bv |
Proteinas f de prefusion del vrs estabilizadas.
|
WO2017207477A1
(en)
|
2016-05-30 |
2017-12-07 |
Janssen Vaccines & Prevention B.V. |
Stabilized pre-fusion rsv f proteins
|
KR102307065B1
(ko)
|
2016-06-20 |
2021-09-30 |
얀센 백신스 앤드 프리벤션 비.브이. |
강력하고 균형 잡힌 양방향성 프로모터
|
ES2963725T3
(es)
|
2016-07-11 |
2024-04-01 |
Opko Biologics Ltd |
Factor VII de coagulación de acción prolongada y métodos para producir el mismo
|
US20190177756A1
(en)
|
2016-08-18 |
2019-06-13 |
The Board Of Trustees Of The Leland Stanford Junior University |
Production and use of phosphoethanolamine cellulose and derivatives
|
AU2017315679B2
(en)
|
2016-08-23 |
2023-12-14 |
Akouos, Inc. |
Compositions and methods for treating non-age-associated hearing impairment in a human subject
|
EP3516064A1
(de)
|
2016-09-20 |
2019-07-31 |
Boehringer Ingelheim Vetmedica GmbH |
Neue promotoren
|
TW201823467A
(zh)
|
2016-09-20 |
2018-07-01 |
德商百靈佳殷格翰維美迪加股份有限公司 |
犬腺病毒載體
|
TW201823465A
(zh)
|
2016-09-20 |
2018-07-01 |
德商百靈佳殷格翰維美迪加股份有限公司 |
新穎豬流感疫苗
|
EA201990711A1
(ru)
|
2016-09-20 |
2019-09-30 |
Бёрингер Ингельхайм Ветмедика Гмбх |
Новый ehv сайт инсерции orf70
|
KR102111244B1
(ko)
|
2017-02-09 |
2020-05-15 |
얀센 백신스 앤드 프리벤션 비.브이. |
이종 유전자의 발현을 위한 강력한 짧은 프로모터
|
JOP20180027A1
(ar)
|
2017-03-28 |
2019-01-30 |
Cell Design Labs Inc |
بوليبيبتيدات مخلطة و طرق لتغيير موضع الغشاء فيها
|
AU2018267971A1
(en)
|
2017-05-17 |
2019-11-07 |
Janssen Vaccines & Prevention B.V. |
Methods and compositions for inducing protective immunity against RSV infection
|
JP7402521B2
(ja)
|
2017-07-11 |
2023-12-21 |
コンパス セラピューティクス リミテッド ライアビリティ カンパニー |
ヒトcd137に結合するアゴニスト性抗体およびその使用
|
MX2020002876A
(es)
|
2017-09-15 |
2020-07-22 |
Janssen Vaccines & Prevention Bv |
Metodo para la induccion segura de inmunidad contra el vsr.
|
EA202090628A1
(ru)
|
2017-09-23 |
2020-11-16 |
Бёрингер Ингельхайм Ветмедика Гмбх |
Система экспрессии paramyxoviridae
|
WO2019089753A2
(en)
|
2017-10-31 |
2019-05-09 |
Compass Therapeutics Llc |
Cd137 antibodies and pd-1 antagonists and uses thereof
|
EP3713961A2
(de)
|
2017-11-20 |
2020-09-30 |
Compass Therapeutics LLC |
Cd137-antikörper und tumorantigenbindende antikörper sowie deren verwendung
|
KR20200090927A
(ko)
|
2017-12-19 |
2020-07-29 |
아카우오스, 인크. |
내이에 대한 치료적 항체의 aav-매개 전달
|
WO2019126358A1
(en)
|
2017-12-22 |
2019-06-27 |
Cell Design Labs, Inc. |
Single- and multi-chain chimeric antigen receptors
|
KR20200124713A
(ko)
|
2018-02-23 |
2020-11-03 |
베링거잉겔하임베트메디카게엠베하 |
외인성 펠라인 파라믹소바이러스 유전자를 발현하는 재조합 바이러스 벡터 시스템 및 이로부터 제조된 백신
|
WO2019179966A1
(en)
|
2018-03-19 |
2019-09-26 |
Boehringer Ingelheim Vetmedica Gmbh |
Ehv insertion site ul43
|
JP7273840B2
(ja)
|
2018-03-19 |
2023-05-15 |
ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー |
不活性化ul18および/またはul8を有する新しいehv
|
SG11202011751WA
(en)
|
2018-06-22 |
2021-01-28 |
Kite Pharma Inc |
Chimeric transmembrane proteins and uses thereof
|
WO2020058341A1
(en)
|
2018-09-20 |
2020-03-26 |
Boehringer Ingelheim Vetmedica Gmbh |
Intranasal vector vaccine against porcine epidemic diarrhea
|
EP3864025A4
(de)
|
2018-10-12 |
2022-07-20 |
Theradaptive, Inc. |
Polypeptide mit einer beta-tricalciumphosphatbindenden sequenz und deren verwendungen
|
BR112021008975A2
(pt)
|
2018-11-13 |
2021-08-17 |
Janssen Vaccines & Prevention B.V. |
proteínas f do rsv pré-fusão estabilizadas
|
MX2021005594A
(es)
|
2018-11-13 |
2021-10-22 |
Compass Therapeutics Llc |
Constructos multiespecificos de union contra moleculas de puntos de control y usos de los mismos.
|
WO2021021674A1
(en)
|
2019-07-26 |
2021-02-04 |
Akouos, Inc. |
Methods of treating hearing loss using a secreted target protein
|
GB201913974D0
(en)
|
2019-09-27 |
2019-11-13 |
King S College London |
Vector
|
CA3164500A1
(en)
|
2020-01-21 |
2021-07-29 |
Kai Christoph Wollert |
Myeloid-derived growth factor for use in treating or preventing fibrosis, hypertrophy or heart failure
|
IL295747A
(en)
|
2020-02-21 |
2022-10-01 |
Akouos Inc |
Preparations and methods for the treatment of hearing impairment that is not related to age in humans
|
TW202144579A
(zh)
|
2020-04-09 |
2021-12-01 |
美商4Mvac有限責任公司 |
病毒載體在冠狀病毒疫苗生產的用途
|
CA3183086A1
(en)
|
2020-05-11 |
2021-11-18 |
Janssen Pharmaceuticals, Inc. |
Stabilized coronavirus spike protein fusion proteins
|
MX2022014167A
(es)
|
2020-05-11 |
2023-02-14 |
Janssen Pharmaceuticals Inc |
Replicón de arn que codifica una proteína de espícula del coronavirus estabilizada.
|
US20210346492A1
(en)
|
2020-05-11 |
2021-11-11 |
Janssen Pharmaceuticals, Inc. |
SARS-CoV-2 Vaccines
|
WO2021231567A2
(en)
|
2020-05-13 |
2021-11-18 |
Akouos, Inc. |
Compositions and methods for treating slc26a4-associated hearing loss
|
US20230212606A1
(en)
|
2020-05-13 |
2023-07-06 |
Akouos, Inc. |
Compositions and methods for treating kcnq4-associated hearing loss
|
GB202009039D0
(en)
*
|
2020-06-15 |
2020-07-29 |
Univ Bristol |
Therapy
|
JP2023531554A
(ja)
|
2020-06-29 |
2023-07-24 |
ヤンセン ファッシンズ アンド プリベンション ベーフェー |
呼吸器合胞体ウイルス感染に対するワクチンの組み合わせ
|
BR112022026974A2
(pt)
|
2020-07-06 |
2023-01-24 |
Janssen Pharmaceuticals Inc |
Proteínas de fusão estabilizadas de proteínas de pico de coronavírus
|
JP2023533528A
(ja)
|
2020-07-08 |
2023-08-03 |
ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー |
Hbvに対するrnaレプリコンワクチン
|
EP4185321A2
(de)
|
2020-07-24 |
2023-05-31 |
Boehringer Ingelheim Animal Health USA Inc. |
Kombinationsimpfstoff gegen schweine
|
EP4243866A1
(de)
|
2020-11-13 |
2023-09-20 |
Boehringer Ingelheim Vetmedica GmbH |
Neuer katzenherpesvirus-impfstoff
|
CA3197936A1
(en)
|
2020-12-01 |
2022-06-09 |
Akouos, Inc. |
Anti-vegf antibody constructs and related methods for treating vestibular schwannoma associated symptoms
|
TW202241935A
(zh)
|
2020-12-18 |
2022-11-01 |
美商世紀治療股份有限公司 |
具有可調適受體專一性之嵌合抗原受體系統
|
TW202245809A
(zh)
|
2020-12-18 |
2022-12-01 |
美商詹森藥物公司 |
用於治療b型肝炎病毒感染之組合療法
|
WO2022146654A1
(en)
|
2020-12-28 |
2022-07-07 |
Janssen Pharmaceuticals, Inc. |
Transcription activator-like effector nucleases (talens) targeting hbv
|
MX2023007800A
(es)
|
2020-12-29 |
2023-07-11 |
Akouos Inc |
Composiciones y metodos para tratar la perdida de audicion y/o la perdida de vision asociada a clrn1.
|
KR20230147156A
(ko)
|
2021-02-19 |
2023-10-20 |
얀센 백신스 앤드 프리벤션 비.브이. |
안정화된 융합 전 rsv fb 항원
|
WO2022175479A1
(en)
|
2021-02-19 |
2022-08-25 |
Janssen Vaccines & Prevention B.V. |
Vaccine combinations against respiratory syncytial virus strain a and b infections
|
WO2022207839A2
(en)
|
2021-04-01 |
2022-10-06 |
Janssen Vaccines & Prevention B.V. |
Stabilized pre-fusion piv3 f proteins
|
WO2023047349A1
(en)
|
2021-09-24 |
2023-03-30 |
Janssen Pharmaceuticals, Inc. |
Stabilized coronavirus spike protein fusion proteins
|
WO2023047348A1
(en)
|
2021-09-24 |
2023-03-30 |
Janssen Pharmaceuticals, Inc. |
Stabilized corona virus spike protein fusion proteins
|
WO2023056329A1
(en)
|
2021-09-30 |
2023-04-06 |
Akouos, Inc. |
Compositions and methods for treating kcnq4-associated hearing loss
|
WO2023070072A1
(en)
|
2021-10-21 |
2023-04-27 |
The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone |
Retroelement-generated transcription factor decoys
|
WO2023081756A1
(en)
|
2021-11-03 |
2023-05-11 |
The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone |
Precise genome editing using retrons
|
WO2023110618A1
(en)
|
2021-12-16 |
2023-06-22 |
Janssen Vaccines & Prevention B.V. |
Stabilized pre-fusion hmpv fusion proteins
|
WO2023141602A2
(en)
|
2022-01-21 |
2023-07-27 |
Renagade Therapeutics Management Inc. |
Engineered retrons and methods of use
|
TW202342525A
(zh)
|
2022-02-02 |
2023-11-01 |
美商阿科奧斯公司 |
用於治療前庭神經鞘瘤相關症狀之抗vegf抗體構築體及相關方法
|
WO2023183627A1
(en)
|
2022-03-25 |
2023-09-28 |
The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone |
Production of reverse transcribed dna (rt-dna) using a retron reverse transcriptase from exogenous rna
|
WO2023183588A1
(en)
|
2022-03-25 |
2023-09-28 |
The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone |
Methods of assessing engineered retron activity, and uses thereof
|
WO2023183589A1
(en)
|
2022-03-25 |
2023-09-28 |
The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone |
Rt-dna fidelity and retron genome editing
|
WO2023217988A1
(en)
|
2022-05-12 |
2023-11-16 |
Janssen Vaccines & Prevention B.V. |
Stabilized pre-fusion hmpv fusion proteins
|
WO2024009280A1
(en)
|
2022-07-08 |
2024-01-11 |
Baylor College Of Medicine |
Integrated stress response inhibitors and methods of using the same
|
WO2024020346A2
(en)
|
2022-07-18 |
2024-01-25 |
Renagade Therapeutics Management Inc. |
Gene editing components, systems, and methods of use
|
WO2024044673A1
(en)
|
2022-08-24 |
2024-02-29 |
The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone |
Dual cut retron editors for genomic insertions and deletions
|
WO2024044723A1
(en)
|
2022-08-25 |
2024-02-29 |
Renagade Therapeutics Management Inc. |
Engineered retrons and methods of use
|
WO2024052563A1
(en)
|
2022-09-08 |
2024-03-14 |
Boehringer Ingelheim International Gmbh |
Myeloid-derived growth factor for use in treating cardiogenic shock
|
WO2024061759A1
(en)
|
2022-09-23 |
2024-03-28 |
Janssen Vaccines & Prevention B.V. |
Stabilized coronavirus s proteins
|
WO2024061753A1
(en)
|
2022-09-23 |
2024-03-28 |
Janssen Vaccines & Prevention B.V. |
Stabilized trimeric class i fusion proteins
|
WO2024061757A1
(en)
|
2022-09-23 |
2024-03-28 |
Janssen Vaccines & Prevention B.V. |
Pre-fusion human piv1 f proteins
|
WO2024074584A1
(en)
|
2022-10-06 |
2024-04-11 |
Janssen Vaccines & Prevention B.V. |
Stabilized pre-fusion piv3 f proteins
|